1. Home
  2. COSM vs LPTX Comparison

COSM vs LPTX Comparison

Compare COSM & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COSM
  • LPTX
  • Stock Information
  • Founded
  • COSM 2009
  • LPTX 2011
  • Country
  • COSM United States
  • LPTX United States
  • Employees
  • COSM N/A
  • LPTX N/A
  • Industry
  • COSM Other Pharmaceuticals
  • LPTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • COSM Health Care
  • LPTX Health Care
  • Exchange
  • COSM Nasdaq
  • LPTX Nasdaq
  • Market Cap
  • COSM 12.3M
  • LPTX 11.1M
  • IPO Year
  • COSM 2013
  • LPTX N/A
  • Fundamental
  • Price
  • COSM $0.99
  • LPTX $0.84
  • Analyst Decision
  • COSM
  • LPTX Hold
  • Analyst Count
  • COSM 0
  • LPTX 1
  • Target Price
  • COSM N/A
  • LPTX N/A
  • AVG Volume (30 Days)
  • COSM 1.2M
  • LPTX 2.0M
  • Earning Date
  • COSM 11-13-2025
  • LPTX 11-12-2025
  • Dividend Yield
  • COSM N/A
  • LPTX N/A
  • EPS Growth
  • COSM N/A
  • LPTX N/A
  • EPS
  • COSM N/A
  • LPTX N/A
  • Revenue
  • COSM $55,093,442.00
  • LPTX N/A
  • Revenue This Year
  • COSM $28.14
  • LPTX N/A
  • Revenue Next Year
  • COSM N/A
  • LPTX N/A
  • P/E Ratio
  • COSM N/A
  • LPTX N/A
  • Revenue Growth
  • COSM N/A
  • LPTX N/A
  • 52 Week Low
  • COSM $0.28
  • LPTX $0.22
  • 52 Week High
  • COSM $1.28
  • LPTX $4.79
  • Technical
  • Relative Strength Index (RSI)
  • COSM 52.27
  • LPTX 74.57
  • Support Level
  • COSM $1.02
  • LPTX $0.46
  • Resistance Level
  • COSM $1.27
  • LPTX $0.40
  • Average True Range (ATR)
  • COSM 0.11
  • LPTX 0.10
  • MACD
  • COSM -0.00
  • LPTX 0.05
  • Stochastic Oscillator
  • COSM 29.83
  • LPTX 75.38

About COSM Cosmos Health Inc.

Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.

About LPTX Leap Therapeutics Inc.

Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.

Share on Social Networks: